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Abstract: The intrauterine device (IUD), primarily in the form of the copper IUD, is used by 
more than 150 million women around the world, making it the most widely used reversible method 
of contraception. With a remarkably low failure rate of less than 1 per 100 women in the first 
year of use, the Copper T-380A is in the top tier of contraceptives in terms of efficacy. Risks of 
utilization include perforation and an increased risk of infection in the first 20 days following 
insertion. Overall, the number of adverse events is low, making the Copper T-380A a very safe 
contraceptive method. The most common reasons for the discontinuation of this method are men-
strual bleeding and dysmenorrhea. However, cumulative discontinuation rates of Copper T-380A 
are lower than that have been reported for other methods, indicating that the Copper T-380A is 
highly acceptable to women. After 5 years, approximately 50% of all women, who have a Copper 
T-380A inserted, will continue to use this highly effective   contraceptive method.
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Introduction
The placement of contraceptive devices in the uterus for the purpose of   preventing 
pregnancy was first described in the scientific literature in the early 1900s. The   original 
intrauterine devices (IUDs) were composed of contraceptive rings made out of a variety 
of materials, ranging from steel to silkworm gut.1–4 However, in the pre-World War II era, 
birth control was not only unpopular, it was considered criminal in many countries 
and led to the arrest of some of the originators of the IUD, including Dr Grafenberg, 
Germany, and Dr Ota, Japan.3,5
In the 1960s, the IUD was reinvented, primarily in the form of inert, plastic IUDs 
that are available in a wide variety of shapes and sizes including the Lippes Loop, 
Margulies Spiral, and Saf-T-Coil.6 In the 1970s, it was discovered that the addition of 
copper to the plastic device improved contraceptive efficacy, thereby allowing it to be 
made smaller, which improved the ease of insertion and decreased some of its untoward 
side effects.6 Of note, use of IUD plummeted in the mid-1970s and mid-1980s when 1 
specific IUD, the Dalkon Shield (A.H. Robins Co., Richmond, VA, USA), was linked 
to septic abortion and pelvic inflammatory disease.6
Today, 2 types of IUDs, containing either copper or progestin, have reemerged 
as effective, safe, and acceptable methods of contraception. Utilized by more than 
150 million women worldwide, primarily in the form of the copper IUD, these devices 
are the most commonly used method of reversible contraception and are second only 
to female sterilization as the most common form of birth control overall.1,7International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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All together, 13.6% of couples around the world have 
selected the IUD for birth control. Utilization rates are not 
homogenous from country to country. IUD use is high (14.5%) 
in less developed countries and low (7.6%) in more developed 
countries.7 Beyond socioeconomic status, rates of IUD use also 
vary on a geographic basis. Central and East Asian countries 
along with Latin American countries report that more than 70% 
of women, who use any form of contraception, use IUD.7 In 
contrast, in Western Europe, approximately 11% of women use 
IUD, whereas in most parts of Africa, less than 1% of women 
use IUD.7 In the United States, utilization of the IUD has been 
low since the 1980s with only 2.1% of contracepting women 
reported IUD use.8
Copper IUDs are typically T-shaped or are composed 
of frameless devices that are anchored to the myometrium 
at the uterine fundus.9 The Copper T-380A, named for the 
380 mm2 of copper surface area, is the most widely used IUD 
worldwide.1 The Copper T-380A has a plastic T-shaped core 
with copper placed around the vertical stem and horizontal 
arms. A silver core within the copper sheath is included to 
prevent fragmentation of the copper, extending the life span 
of the Copper T-380A past some of the older copper IUDs.
A higher surface area of copper results in higher   contraceptive 
efficacy. Compared with older copper IUDs, which typically 
had less than 350 mm2 of copper surface area, the Copper 
T-380A has been able to achieve superior contraception while 
maintaining a similar side-effect profile.9–11 Like many of the 
IUDs, the frame of the Copper T-380A is connected to a mono-
filament thread that protrudes through the cervical canal into 
the upper vagina. This facilitates easy removal and allows the 
user to ensure that the IUD remains in the uterus.
Mechanism of action
The primary mechanism of action of the copper IUD is the 
prevention of fertilization through a cytotoxic inflammatory 
reaction that is spermicidal.12 In copper IUD users, the   copper 
concentration in cervical mucus is substantial and leads to 
an inhibition of sperm motility.13 Because copper ions also 
result in significant endometrial changes, sperm migration, 
quality, and viability at the level of the endometrium is hin-
dered. This effect is believed to be the primary mechanism 
by which the copper IUD provides contraception.14 Several 
investigators have attempted to recover spermatozoa from 
the fallopian tubes of women using an IUD and from control 
subjects not using an IUD. Spermatozoa recovery techniques 
varied between studies and sometimes were not reported 
in adequate detail to allow for duplication. Nonetheless, 
after both groups were inseminated, dramatically reduced 
numbers of spermatozoa were recovered from the   ampullary 
portion of fallopian tubes in women using a copper IUD in 
situ.13,15–17
There is evidence to suggest that the copper IUD also 
works by impairing implantation. Investigators exploring 
biochemical evidence of fertilization in copper IUD users 
have measured 2 indicators of fertilization, early pregnancy 
factor (EPF) and human chorionic gonadotropin (hCG). 
EPF and hCG have been detected in a limited number of 
copper IUD users (,1%).13,18–20 It is important to note that 
many of these studies used earlier generation copper IUDs 
with a copper content lower than that in the Copper T-380A. 
Also, the assays may have been affected by cross reactivity 
with hormonal markers. There is also indirect clinical evi-
dence that the copper IUD has postfertilization contraceptive 
effects. Placing a copper IUD, even in the early luteal phase, 
is a highly effective emergency contraceptive.21
Efficacy
Several investigators have examined the efficacy of various 
copper IUD devices. A Cochrane review published by Kulier 
et al10 in 2007 examined 35 randomized controlled trials that all 
together included more than 50,000 women and made 16 differ-
ent comparisons of efficacy from the scientific literature. The 
authors concluded that the Copper T-380A was more effective in 
preventing pregnancy than the other devices including the Mul-
tiload 375, Multiload 250, Copper T-220, and Copper T-200.
Although Copper T-380A is approved for use in the 
United States for 10 years and is licensed for use in 
the United Kingdom for 8 years, it has been shown to con-
sistently maintain its efficacy for 12 years.22 Most failures 
will occur in the first year after insertion. Still, the annual 
pregnancy rate, including both intrauterine and ectopic 
pregnancies, for the first year of use is quite low, between 
0.5 and 1.0 per 100 women.10,22,23 The published cumula-
tive pregnancy rate for the remaining contraceptive life 
span of the Copper T-380A has been consistently very low. 
An interim analysis of an ongoing, large, multinational 
study reported a total pregnancy rate of 1.7 per 100 women 
for the first 3 years of use.24 Other large studies have 
reported the cumulative pregnancy rate of 1.5 per 100 women 
for the first 7 years of use.22,25 The cumulative pregnancy rate 
appears to be extremely low after the seventh year. Pooled 
data from 2 large studies (n = 4,932) demonstrated no preg-
nancies after the eighth year of use.22,25 After 12 years of use, 
a large multinational study conducted by the World Health 
Organization reported that the cumulative pregnancy rate for 
the Copper T-380A was 2.2 per 100 women.22,25International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Considering pregnancy prevention, the high efficacy of 
the Copper T-380A places it in the top tier of contraceptive 
  methods and makes it comparable to the 10-year pregnancy 
rate of 1.9 per 100 women that has been reported in women 
who have undergone surgical sterilization.26 There are also 
some small studies that have suggested that the Copper 
T-380A can be used beyond 12 years. A study conducted 
by Bahamondes et al27 in Brazil, followed a small group of 
women using Copper T-380A for contraception for a total 
of 16 years. Although the majority of women who had used 
the Copper T-380A for 10 years chose to discontinue it after 
they were informed it was only approved for use for 10 years, 
45% of subjects were still using the Copper T-380A at 12 
years with no reported pregnancies. After 16 years of use, 
there were still no reported pregnancies; although by this 
time, nearly 80% of subjects had stopped using the Copper 
T-380A. The mean age of the study population at the 10-year 
mark was 38.4 years. A study conducted by the Population 
Council followed women using the Copper T-380A through 
20 years. The small number of subjects contributed a total 
of 70 woman-years of observation between 15 and 20 years, 
and during this time period, no women became pregnant.28 
In both studies, the reported high contraceptive efficacy may 
have been related to the fact that women who have used an 
IUD for more than 12 years are typically older, with decreased 
fertility rates. Although adequate data is clearly lacking, the 
authors of these studies hypothesized that women as young as 
25 could potentially use a Copper T-380A for contraception 
until menopause.28
Contraceptive failure with the  
Copper T-380A
Several studies have demonstrated that younger women are 
more likely to experience contraceptive failure with a copper 
IUD than older women.29 However, it should be noted that the 
copper IUD is still more efficacious than other contraceptive 
methods in this age group. In particular to the Copper T-380A, 
a nested case-control study of women using various forms of 
a copper IUD showed that young age was a significant risk 
factor for experiencing a contraceptive failure.30 Because 
various copper IUDs were used, statistical adjustment was 
made for copper surface area (copper surface area of less than 
350 mm2 significantly increased the likelihood of contracep-
tive failure). Compared with women younger than 25 years 
of age, women older than 35 years were significantly less 
likely to experience a failure (odds ratio [OR] = 0.2; 95% CI, 
0.1–0.7). The odds of experiencing a contraceptive failure 
with the Copper T-380A at 40 years or more compared with 
women younger than 25 years was even lower (OR = 0.0; 
95% CI, 0.0–0.3). In several studies, parity, uterine position, 
and uterine size were not associated with an increased risk 
of contraceptive failure.31,32 However, suboptimal placement 
of the IUD within the cervix increased the likelihood of con-
traceptive failure.14,33 If an IUD is placed in the cervix, the 
likelihood of contraceptive failure was   significantly increased 
(OR = 13.93; 95% CI, 4.13–48.96).
Although it has been hypothesized that anti-inflammatory 
medications, including aspirin, and other nonsteroidal 
  anti-inflammatory medications could increase the risk of con-
traceptive failure with an IUD, there is no scientific evidence 
on this. A case-control study published in 2006 found no 
differences in the types of medications taken among women 
who had a confirmed pregnancy with an IUD in place and 
those who did not.34 Another case-control study published in 
1989 found that aspirin use was associated with contraceptive 
failure with a copper IUD.35. However, in this study, the same 
relationship was not confirmed for other anti-inflammatory 
medications, leading investigators to question the validity of 
the association.
The overall risk of ectopic pregnancy is decreased in 
women using a Copper T-380A. Rates of ectopic pregnancy 
in women who do not use contraceptives are reported to be 
between 3.00 and 4.50 per 1,000 woman-years, whereas 
rates of ectopic pregnancy in women using a Copper 
T-380A are reported to be 0.20 per 1,000 woman-years.36,37 
Thus, the IUD is protective against ectopic pregnancy, 
making women who use the Copper T-380A likely to 
have an ectopic pregnancy 90% less than women using no 
contraceptives.36 As a consequence, a prior history of an 
ectopic pregnancy is not a contraindication to IUD use. 
In patients with a history of prior ectopic, an IUD would 
be a better choice than no contraception or a less reliable 
method. In addition, previous use of an IUD does not 
increase a woman’s risk of an ectopic pregnancy.38–40 How-
ever, if a pregnancy occurs with an IUD in place, there is a 
relatively high ratio of ectopic to intrauterine pregnancies, 
with approximately 6% of pregnancies among copper IUD 
users being ectopic.36
If an intrauterine pregnancy does occur with an IUD in situ, 
the spontaneous abortion rate is estimated to be 40%–50%.41 
If the woman wishes to continue the pregnancy and the strings 
are visible, removal should be attempted if it can be done with-
out placing instruments in the uterus. If the IUD is successfully 
removed, the rate of spontaneous abortion is lowered to 20%.41 
There is no evidence of an increased risk of teratogenesis to 
infants born to women with an IUD in situ.42International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Safety
Effective methods of contraception, such as the Copper T-380A, 
have allowed many women around the world to avoid the health 
risks of unwanted pregnancy and have   provided for the spacing 
of pregnancies. This has contributed to improvements in infant 
and child survival. There are only a handful of adverse events 
that accompany the Copper T-380A use including perforation, 
expulsion, and infection. These infrequent events should always 
be viewed in perspective with the multiple health benefits 
associated with the ability to plan fertility.
IUD-associated adverse events
Perforation of the uterus occurs at the time of IUD insertion 
at a rate of 1–2 per 1,000 insertions.43,44 A study that included 
more than 21,000 insertions through pooled data from mul-
tiple international studies estimated the rate of perforation to 
be 1.5 per 1,000 insertions for the Copper T-380A.43 Factors 
associated with an increased risk of perforation include skill 
of the clinician and anatomic factors, such as a stenotic cervix 
or an immobile or a retroverted uterus.43 Of note, no particular 
IUD has been found to be easier to insert or more likely to 
perforate than the others.9
Most perforations are not recognized at the time of 
insertion and are discovered when there is a shortening or 
disappearance of the IUD strings or when the patients pres-
ent with pregnancy. Although serious complications due to 
a perforated IUD are rare, it is generally recommended that 
the copper IUDs to be retrieved as soon as possible. Copper 
ions are inflammatory, and there are multiple case reports of 
intra-abdominal copper IUDs eroding into the bladder or the 
gastrointestinal tract, typically the small bowel.45
Comparative randomized clinical trials have reported expul-
sion rates to be lower with the Copper T-380A than with other 
copper IUDs. Expulsion is most likely to occur in the first year 
after insertion and can occur at any time during the 10-year 
period of use.44 In a large study of 427 women, there were no 
expulsions reported after the first year of use. This finding is 
somewhat atypical as most studies have found a small number 
of IUD expulsions continue to occur after the first year of use. 
Reported cumulative expulsion rates are 2.4%–6.0% for the first 
year of use, 3.4%–6.7% at 2 years, 4.4%–5.4% at 3 years, and 
11.2% at 10 years.44,46–49 Expulsion tends to occur at the time 
of menstruation and is often associated with cramping, vaginal 
discharge, and bleeding. If a partially expelled IUD is noted on 
physical examination, it should be removed and replaced as long 
as there are no signs of pregnancy or infection. The only fac-
tors that have been consistently associated with a higher rate of 
expulsion are age younger than 20 years and nulliparity.5,44,47
A study by Mishell et al50 published in 1966 demonstrated 
that the uterus is routinely contaminated with bacteria at the 
time of IUD insertion. Since that, one of the primary concerns 
with IUD utilization has been the risk of upper genital tract 
infection and the concern that an in situ IUD could result in 
an ongoing risk of pelvic inflammatory disease. However, 
large studies performed in a variety of clinical settings and 
  geographic locations have demonstrated that the insertion 
process rather than the in situ IUD increases the risk of 
infection.51 Even at the time of insertion, the increased risk 
of infection remains in an acceptably low range. In a review 
of data from 12 clinical trials conducted by the World Health 
Organization that included nearly 23,000 IUD insertions, 
the rate of pelvic inflammatory disease was 9.68 per 1,000 
woman-years in the first 20 days after insertion and 1.39 per 
1,000 woman-years thereafter.51 In total, pelvic inflammatory 
disease was identified in 1.6 cases per 1,000 woman-years 
for the whole duration of use. Although the risk of pelvic 
inflammatory disease was more than 6 times higher in the 
first 20 days after insertion (relative risk [RR] = 6.30; 95% 
CI, 3.42–11.6), it decreased to a rate similar to reproductive-
aged women who were not using an IUD for contraception 
in subsequent years.51
The logical question of the utility of antibiotic prophylaxis 
at the time of insertion was addressed in a Cochrane review 
by Grimes et al in 2001.52 The 4 randomized clinical trials, 
addressing antibiotic prophylaxis at the time of IUD inser-
tion, showed that doxycycline or azithromycin administered 
at the time of insertion does not decrease the risk of upper 
genital tract infection (RR = 0.9; 95% CI, 0.5–1.5).52 Although 
antibiotics did result in a small reduction in unscheduled 
visits following IUD insertion (RR = 0.8; 95% CI, 0.7–1.0), 
it did not decrease the likelihood of removal within 90 days 
(RR = 1.1; 95% CI, 0.7–1.6). Of note, based on a study 
performed in a geographic locale with a high prevalence of 
sexually transmitted diseases, Grimes et al concluded that 
prophylaxis might be warranted for women living in similar 
high-risk regions.53
Relevant contraindications
Because product labeling and practice guidelines can vary 
from country to country, many experts have highlighted the 
importance of incorporating relevant contraindications when 
considering the utilization of the Copper T-380A.54 Because 
the copper IUDs are completely nonhormonal, they can be 
used safely in women who have contraindications to exog-
enous estrogen and progestins, including women with active 
liver disease and women at risk for venous thromboembolism. International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Absolute evidence-based contraindications are few in 
number. With the Copper T-380A, there are 5   distinct catego-
ries of contraindications: infection, pregnancy, uterine factors, 
gynecologic cancer, and adverse reactions to copper.
It is estimated that uterine anomalies occur in   approximately 
4% of reproductive-aged women.55 Severe uterine distortion 
and anomalies, like cervical stenosis, large fibroids, or a 
uterine septum, can make insertion more difficult and may 
increase the risk of expulsion. However, if the uterine cavity 
can be safely entered and it does not appear to be distorted, the 
Copper T-380A can be placed.56 Identification of pregnancy 
is an obvious contraindication to the use of a Copper T-380A 
device. Although there is no direct evidence of harm in using 
a copper IUD in women with Wilson’s disease, it would seem 
prudent to seek other contraceptive methods because these 
women are unable to metabolize copper.
In terms of gynecologic cancer and unexplained, abnormal 
uterine bleeding suspicious for cancer, evaluation would ide-
ally begin prior to IUD placement. Because some gynecologic 
malignancies present with irregular and heavy bleeding, place-
ment of a copper IUD in women with these symptoms may 
delay diagnosis and worsen bleeding patterns. However, as in all 
areas of medicine, risk and benefit must be considered, and this 
caution should be weighed against the need to provide effective 
contraception. In some low-resource settings, timely diagnosis 
and treatment of gynecologic cancers are not possible, and 
if the likelihood of pregnancy is high, the benefit of preventing 
pregnancy in a woman, who may have cancer, may outweigh 
the potential risks associated with the placement of the IUD.
Concern about the risk of pelvic inflammatory disease has 
long hindered the use of the IUD. IUD insertion is generally 
contraindicated if an active cervical infection is identified. 
This is based on indirect rather than direct evidence. A system-
atic review of the literature published in 2006 did not identify 
any comparative studies of contraceptive insertion in the pres-
ence of a cervical infection versus no infection.57 However, 
there is indirect evidence from 6 prospective studies, in 
which an IUD was inadvertently placed in the presence of a 
sexually transmitted cervical infection. An analysis of these 
studies suggests that even in the presence of these infections, 
the risk of pelvic inflammatory disease is still low. In women 
who had negative cervical cultures, the risk of pelvic inflam-
matory disease with IUD placement was 0%–2%, whereas in 
the presence of infection, it was 0%–5%.57 Again, a reason-
able assessment of the risks and benefits should be weighed 
because areas with high rates of unintended pregnancy may 
have high rates of sexually transmitted infection and may lack 
laboratory facilities to test for infection.
Acceptability
Many aspects of the Copper T-380A make it an ideal con-
traceptive method for many women. In addition to   providing 
long-lasting, highly effective contraception, it does not 
interfere with sexual intercourse, does not interact with 
medications, is immediately reversible, and is not subject to 
forgetfulness or changes in medical supply. Moreover, the 
IUD does not have any hormone-related side effects or con-
traindications, and it does not affect breastfeeding. There is 
also no evidence to suggest that the copper IUD is associated 
with weight gain, altered libido, or mood changes.58,59
However, with all types of copper IUDs, periods can 
become longer and heavier, and there is an increased likeli-
hood of   dysmenorrhea.14 Menstrual blood loss increases by 
approximately 50% and the increase persists for the duration 
of IUD use.60 Although this increase in blood loss typically 
does not cause clinically significant anemia, depletion of iron 
stores, as evidenced by serum ferritin levels, is seen after 
more than 1 year of use.61
Consequently, bleeding and dysmenorrhea are the most 
frequent reasons for copper IUD discontinuation. In the 
first year of use, between 4% and 15% of women using a 
  Copper T-380A will have it removed for these reasons.5,24,62 
In a multinational study (n = 427) that included the United 
States and the   European countries, 13.8 per 100 women using 
the Copper T-380A discontinued the IUD over the course of 
the first year, with 6.9 per 100 women discontinuing because of 
pain or bleeding.63 In another multinational study (n = 441) that 
was conducted in Yugoslavia and Panama, the discontinuation 
rate was 10 per 100 women, with 5 per 100 women discon-
tinuing because of pain and bleeding.48 Other reasons for IUD 
discontinuation included infection and a desire for fertility.64 
Although the discontinuation rate of the Copper T-380A is 
significant, it is important to note that 1-year continuation rates 
are higher than that has been reported with other methods. 
For example, in the United States, after 1 year, 78% of women 
will continue to use the Copper T-380A compared with 68% 
of women who were given oral contraceptive pills and 56% 
of women who received injectable contraception.65
In subsequent years, cumulative discontinuation rates 
continue to increase to 22%–33% after 3 years, 60% after 5 
years, and between 60% and 72% after 10 years of use.44,48,66–68 
In general, approximately 50% of all patients who have a 
  Copper T-380A will discontinue it within 5 years. Conversely, 
after 5 years, approximately 50% of all patients will still be 
using this reliable and effective form of contraception.
Because bleeding and pain are the primary reasons, 
some women chose to have their IUDs removed, and several International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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  investigators have focused on the treatment of these side 
effects. A Cochrane review analyzed 15 randomized con-
trolled trials that included more than 2,700 women, from 
10 countries, who used nonsteroidal anti-inflammatory drugs 
(NSAIDS) to decrease pain and bleeding with a copper IUD.69 
All NSAIDS, including naproxen, sprofen, mefenamic acid, 
ibuprofen, indomethacin, flufenamic acid, alcolofenac, and 
diclofenac, reduced pain and bleeding in women who com-
plained of these symptoms. However, prophylactic adminis-
tration of NSAIDs after insertion did not decrease complaints 
of pain or bleeding or increase continuation rates.62
Small alterations to the Copper T-380A have also not made 
a significant difference in side effects. The Copper 380 Slimline 
(TCu380S) differs from the Copper 380A in that the copper 
sleeves cover the lateral ends of the horizontal arms rather 
than encircling the middle of the arms. However, this   modification 
failed to change the rates of bleeding, pain, or discontinuation 
and also did not change the efficacy of the device.10
Special groups
Nulliparous women
The length, width, and volume of the uterine cavity of nul-
ligravid women tends to be smaller than the cavity of gravid 
women.70 This led to initial concerns that the Copper T-380A 
may be too large to use in nulliparous women. Although 
most experts advocate for the utilization of IUDs in women 
who have never had a child, a Cochrane review published in 
2006 addressing this topic noted that there were relatively 
few studies in the medical literature and concluded that 
the optimum device for nulliparous women has yet to be 
established.71 A smaller version of the Copper T-380A, the 
Copper T-380Nul, which is similar in shape and in copper 
content but is smaller in length and width, is manufactured 
and used in Mexico.
A randomized controlled trial that included 1,170 nul-
liparous women using the standard Copper T-380A, the 
Copper T-380Nul, and the Multilaod Copper 375sl dem-
onstrated lower expulsion rates (3.3% vs 1.8%, P , 0.001) 
and higher continuation rates (85.4% vs 29.5%, P , 0.001) 
in nulliparous women with the Copper T-380Nul compared 
with the traditional Copper T380A while maintaining com-
parable efficacy.72 As in parous women, most removals were 
performed because of bleeding and pain. It is notable that 
in this particular study, the continuation rate of the Copper 
T-380A in nulliparous women was quite low at 29.5% (±12.9) 
at 1 year. Another study of the Copper T-380A in nulliparous 
women reported a expulsion rate of 6% and a removal rate 
of 14% in the first year.32
With all women, particularly with nulliparous women, 
future fertility is an important issue. After cessation of the use 
of a copper IUD, return of fertility is rapid.73 In a study by Doll 
et al74 return to fertility within 1 year was no   different in women 
using a barrier method, a copper IUD or oral   contraceptive 
pills. In a case – control study published by Hubacher et al75 
previous use of a copper IUD was not a risk factor for infertility 
although the presence of chlamydial antibodies in both previous 
users and nonusers of the IUD was a risk factor for infertility. 
The risk of tubal occlusion following the use of the copper 
IUD is compared to the risk with other contraceptive methods 
in Figure 1. Thus, in the absence of other contraindications, a 
concern about future fertility should not be a deterrent to copper 
IUD use in nulliparous women.
Adolescents
Expert opinion also suggests that the Copper T-380A can be 
used in adolescents. However, there are little data regarding 
safety, efficacy, and acceptability of IUDs in this popula-
tion.76 A systematic review published by Deans et al 77 identi-
fied 6 cohort and 7 case series reports addressing IUD use 
in adolescents. However, none included the Copper T-380A. 
There is 1 pilot study (n = 23) that was published in 2010 
that was conducted in the United States where adolescents 
were randomized to a levonorgestrel IUD or a Copper 
T-380A.78 After 6 months, only 45% of adolescents who 
received the Copper T-380A were still using it. Of the 11 
subjects, who received a Copper T-380A, 2 experienced a 
partial expulsion, 1 had removed it at the time of sponta-
neous abortion, and 4 requested removal because of pain 
and bleeding.
2.0 1.8 1.6 1.4 1.2 1.0 0.8 0.6 0.4 0.2
Any copper IUD
Condoms or
hormonal
methods
Hormonal
methods only
Condoms only
0
Figure 1 Previous use of contraceptives and risk of tubal occlusion presented as 
odds ratios and 95% Confidence Intervals.
Note:  Women  with  no  previous  use  of  contraception,  rhythm  method  or 
withdrawal comprised the reference group. Hormonal methods only included oral 
contraceptives or injectables. From data of Hubacher et al 2001.75International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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With this paucity of data, it is difficult to comment on the 
use of the Copper T-380A in adolescents. However, this should 
be countered with the pressing need to prevent unintended 
pregnancy in this group of women. Young age and associated 
high fertility is likely to confer a higher risk of pregnancy in 
young women compared with older women using the Copper 
T-380A. However, the contraceptive   efficacy of the Copper 
T-380A is still likely to be higher than that with other meth-
ods.36 Although women younger than 20 years are more likely 
to request IUD removal because of pain and bleeding and 
are more likely to experience an expulsion. Discontinuation 
rates of all types of contraceptives in this age group is higher 
than that in adult women.79,80 Of note, there is no evidence to 
suggest that rates of infection associated with IUD insertion 
are higher in adolescents than in adults.
emergency contraception
Emergency contraception prevents pregnancy after 
unprotected intercourse has occurred. Unlike hormonal 
emergency contraceptives, the copper IUD works by pre-
venting implantation and can be inserted up to 120 hours 
after unprotected intercourse.81 Utilization of the Copper 
IUD as an emergency contraceptive has the added benefit 
of providing long-term, highly effective contraception 
in a group at risk for unintended pregnancy. However, in 
most places, the Copper T-380A is underutilized for this 
purpose.
Recommendations regarding the use of a copper IUD 
as an emergency contraceptive are based on observa-
tional s  tudies conducted in China. In a study of almost 
2,000 women, insertion of the Copper T-380A within 120 
hours after   unprotected intercourse resulted in only 2 preg-
nancies (0.13%) over the course of a year.82 A meta-analysis, 
which included multiple types of copper IUDs, reported 
only 1 pregnancy in 879 women who used a copper IUD 
after unprotected intercourse and estimated the pregnancy 
rate with postcoital IUD insertion to be 0.1%. A pregnancy 
rate much lower than the 1.5% quoted for a single dose of 
levonorgestrel.83,84
Postabortion and postpartum insertion
In many ways, insertion of IUDs in the postabortion and 
  postpartum setting is ideal. Women are highly motivated to 
use contraception at this time and are often in a health care 
setting with clinicians capable of inserting the devices.85 
A Cochrane review on this topic identified 9 appropriately 
described randomized studies addressing postabortion 
insertion.85 Perforations and infections were rare despite 
pregnancy-related changes, and the risk of these events 
was similar to those reported for delayed insertion.51,53,87,88 
However, none of the studies described in the Cochrane 
review used the Copper T-380A device.86 Only 1 study 
directly compared immediate vs delayed insertion of a Copper 
7 IUD, and there was a nonsignificant increase in the risk of 
expulsion with immediate postabortion insertion (RR = 5.69, 
95% CI 0.75, 43.08).89 In this randomized study, it is impor-
tant to note that 42% of women randomized to delayed inser-
tion group did not return for insertion. A benefit that likely 
counters the probable increased risk of expulsion.
A systematic review addressed insertion of IUDs in the 
postpartum period.90 Although the studies identified in this 
review were of poor to fair methodological quality and risk 
estimates varied considerably between studies, there were 
some consistent conclusions. Rates of adverse events, such 
as infection and perforation, were low. In terms of expul-
sion, insertion within 10 minutes of placental delivery led 
to lower expulsion rates than when insertion took place 
between 10 minutes and 72 hours.90 In a prospective cohort 
study, 36.9% of Copper T-380A IUDs were expulsed when 
placed less than 10 minutes after placental delivery com-
pared with 69.8% in the later postpartum period and 6.9% 
in the 6-week postpartum group (P , 0.003).91 Another 
study using the Copper T-380A and the multiload copper 
375 inserted less than 10 minutes after delivery of the 
placenta reported an expulsion rate of 9% after cesarean 
section and 13% after vaginal delivery. After 1 year, 16% 
of women in the cesarean section group and 6% of women 
in the vaginal delivery group requested IUD removal.92 
Finally, the addition of a chromic suture to anchor the IUD 
has not been shown to decrease the risk of expulsion and 
hand insertion is comparable to insertion with a sponge 
forcep, so either technique can be used.93
Summary
The Copper T-380A is an extremely effective, safe, long 
lasting, rapidly reversible method of contraception that does 
not interfere with intercourse, is not subject to forgetfulness, 
and once inserted, is not subject to changes in medical supply 
or access to health care. It is also nonhormonal, so it does 
not have any hormone-related side effects or contraindica-
tions and does not affect breastfeeding. These aspects have 
contributed to its popularity worldwide.
As described in this review, there are downsides to the 
utilization of the Copper T-380A. It requires a trained clinician 
to insert, and its use is associated with increased menstrual 
bleeding and pain. These side effects can lead to discontinuation International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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of this method. There are also some adverse events associated 
with IUD use, including perforation and an increased infec-
tion immediately following insertion. However, rates of these 
complications are remarkably low and are easily countered by 
the health benefits women and their families experience from 
the prevention of unintended pregnancy.
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